Today’s dementia treatment is ineffective. Something must soon happen. Let’s stay awake.

The number of dementia patients in the world is estimated to reach 132 million in 2050, an increase of 300 percent from 47 million, according to a report from Alzheimer’s Disease International. Source: Swedish Today’ s Medicine (DM) 2015-08-25.

Sweden, with 10 million inhabitants is one of the most long-lived populations in the world.

Over 1,6 million or 16 percent are +70 years.More than 160 000 Swedes are suffering from dementia. The majority (60 – 70 percent) have the dominating form of dementia, Alzheimer’ s disease.
Dementia is diagnosed in 8 percent of people older than 65 years, in 20 percent older than 80 years and almost in half of those older than 90. There are at least 80 different dementia diseases.

To fight the dementia diseases effectively there is a need for better diagnostics and prognostics (“early warning systems”), better treatment and better (meaning non-anticholinergic) prescriptions drugs in general.
A full range of dementia tailored prescription drugs, when will it appear?

A recently published article Common drugs linked to increased risk of Alzheimer’s puts the light on the problem.
Quote: “Anticholinergic medications may increase the risk of accelerated cognitive decline, especially in older adults at high risk of developing Alzheimer’s disease.”
The article by James Kingsland, is published in MedicalNewsToday on September 16, 2020. Facts checked by Allison Kirsop, PhD.
Quote: “Anticholinergic drugs block the action of acetylcholine, a chemical messenger that controls a range of automatic bodily functions and plays a vital role in memory and attention. Doctors prescribe these drugs for a variety of conditions, including urinary incontinence, overactive bladder, chronic obstructive pulmonary disorder (COPD), seasonal allergies, and depression.”

Also please note a study from Karolinska Institutet Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia, published May 2020.
https://doi.org/10.1002/alz.12113

“Should be punishable.”
“To medicate a person with a dementia disease is as difficult as medicating a premature baby. But imagine that the health care system would treat an infant as ignorant as it treats elderly.”
Dr Yngve Gustafson, geriatric professor, Umeå University, is well known by the public as a fighter for better dementia health care. He is upset and critical of the poor treatment the dementia patients generally get.
“Prescribing wrong drugs and drugs in too high doses is common. Some prescriptions are made over the phone by doctors without even having examined the patient. That should be punishable.”
Source: Swedish Dementia Association’ s (Demensförbundet) home page.

Summary
The dementia market is still dormant and unclear. The patients often have a low status in the health organization, a consequence of lacking effective treatment. Dementia patients have no voice in the media.
When “dementia tailored” products will be introduced, dementia awareness will increase, market will wake up requesting more effective products, better information etc. We’ve seen this happen time and again.

Keeping an eye on this “ticking bomb market” can therefore be fruitful.
Also, Nordic countries are good test markets for new dementia products.

//COB

×
Mats Erasmie

Mats Erasmie

Chairman of the board Simplex Motion AB. Consultant in Leadership and Business Development, Erasmie&Erasmie AB.

Key Competence

Sales, Leadership as a part of a strategic changes.

Education
  • MBA, International marketing, University of Stockholm.
  • Certified in Authentic Leadership,Transaction Analysis, Situational Leadership (SL II, Blanchard)
  • Certifed in Insight Discovery, Certifed in DISC
Experiences
  • Consultant in Leadership and Business Development.
  • Erasmie&Erasmie AB.
  • Chairman of the board Simplex Motion AB.
  • Consultant at Booster Group AB, business development and negotiations.
  • Teacher at IHM, Market Analysis, Practical Marketing and Negotiations.
  • CEO, Chairman of the board and partner; Sällma AB.
  • Vice President Marketing & Sales, Consultant in Leadership and Business.
  • Development at Cordovan Performance Sweden AB.
  • CEO at Lucky Punk AB.
Publications

Books and training packages, marketing and sales, twelve in total since 1999

  • ”MED KUNDEN I FOKUS”, Liber Ekonomi 2000
  • ”KUNDRELATIONEN”, Liber Ekonomi 2001
  • ”FÖRSÄLJNING OCH SERVICE”, Liber Ekonomi 2003
  • ”PERSONLIG FÖRSÄLJNING 1”, Liber Ekonomi 2012
  • ”PERSONLIG FÖRSÄLJNING 2”, Liber Ekonomi 2014
  • ”Dödskaravanen”, Historical novel, 2018
  • ”Silverfloden”, Historical novel, 2019
  • Various articles in the magazines Ledarskap, Affärsvärlden and Dagens Industri.

What Now?

You have defined your interest area and the questions related to this.

Now fill in the form and send it to us. The defined contact person from GHN Pharma Nordic will review your interest and contact you within 48 hours.

×

Get a Contact Person

×
Pontus Bergman

Valdet Hetemi

Head of Operation & Logistics

Key Competence

Over 17 years of experience within the Pharmaceutical industry; Rx, Medical Devices, Metabolic Diseases, OTC, Logistics and Supply Chain, Business Strategy, Finance, Sales and Marketing, Start-Ups.

Education
  • Education: Master of Business Administration and Bachelor of Social Sciences from the University of Lund and University of Cologne.
Experiences
  • Head of Operations at POA Pharma Scandinavia AB, Country Manager Sweden at Vitaflo Scandinavia AB/ Navamedic AB, Finance Manager at Vitaflo Scandinavia AB/Navamedic AB.

×
Ingvar Bosaeus

Martin Svahn

RP& Pharmacist

Key Competence

Martin Svahn is a licensed pharmacist and pharmacy manager.

Education

Licensed Pharmacist at the Universitet of Uppsala, Magisterthesis at the Departement of Anaesthesiology,,University of Uppsala. Master's Program in Clinical Pharmacy University of Uppsakla.

Experiences
  • Start-up of a new privately owned pharmacy. . Worked in 2013 at K3 as GSST, Since 2014 pharmacy manager at three pharmacies with responsibility for 13-20 employees and an annual turnover of 80 million. "Cluster manager" for Kronan's pharmacy Halland.
×
Mats Erasmie

Andreas Larsson

Finance Manager

Key Competence

Experience within the Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases and OTC regarding Accounting and Finance Strategy, Financial reporting, Business Development and Logistical support

Education
  • Master of Aeronautical Science at the University of Embry-Riddle Aeronautical University and a degree at the KY academy of finance and accounting at Studium in Gothenburg.
Experiences
  • Accounting manager at POA Pharma Scandinavia AB, POA Pharma North America and Adrian & Partners AB.

×
Pontus Bergman

Pontus Bergman

PB Lawyer, founder of Bergman & Eek Advokat AB.

Key Competence

Principal felds of practice are strategically planning for privately owned companies regarding all legal and economical matters. Special focus on developing and establishing new companies or activities abroad, including international tax law for companies and employees.

Education
  • Education: Master of Law from University in Lund
Experiences
  • Partner at Setterwalls Law Firm
  • Member of the board of POA Pharma AB and in several Swedish privately-own companies.

×
Tina Madsen Sandström

Tina Madsen Sandström

CEO GHN Pharma AB

Key Competence

Over 35 years experience within the international Pharmaceutical industry Rx, Medical Devises, OTC and   Rare Metabolic Diseases. Administration, Leadership, , Licenses & Acquisitions, Start-ups Development, Development, Management, Leadership.

 

Education

Merkonom, Educated at Hillerød Business School

Experiences
  • Managing Director for Pharma-Vinci A/S, Member of the branch organisation BFID
  • CEO Vitafo Scandinavia AB
  • CEO POA Pharma Scandinavia AB
  • Director of the board Vitafo Scandinavia AB
  • Director of the board POA Consulting AB
  • Director of the board POA Pharma Scandinavia AB
×
Roland Sandström

Roland Sandström

COB GHN Pharma AB

Key Competence

45 years experience within the international Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases, OTC. Commercial Strategy, Business Development, License & Acquisitions, Start-ups Development,Management, Organisation Theory.

Education

Master of Political Science at the University of Lund

Experiences
  • Managing Director Meda Sweden
  • Board member of LSAB and LIF
  • COB Vitafo Scandinavia AB
  • Director of the board Navamedic
  • COB POA Consulting Scandinavia AB
  • COB POA Pharmas Scandinavia AB
  • COB POA Pharma North America
Publications
  • Kunden som Kompis (Customer as a Pal)
  • Articles around Project work, organisation theory and marketing
  • Lectures and abstract publications at IPMA in Paris and Ljubljana